Cohance Lifesciences Limited
NSE: COHANCE BSE: COHANCE
NSE
387.00
16.30 (4.40%)
Prev Close
370.7
Open Price
390
Volume
145,648
Today Low / High
382.15 / 399.45
52 WK Low / High
355.7 / 1123.4
Range
368 - 406
BSE
386.35
15.35 (4.14%)
Prev Close
371.00001
Open Price
389.60001
Volume
16,266
Today Low / High
383 / 398.9
52 WK Low / High
355.65 / 1328.2
Range
367 - 406
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 387 (target range: 368 - 406), reflecting a change of 16.3 (4.39709%). On the BSE, it is listed at 386.35 (target range: 367 - 406), showing a change of 15.34999 (4.13746%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
03 Feb
390.00
-1.24%
02 Feb
369.90
0.22%
01 Feb
382.90
-3.40%
30 Jan
375.05
1.67%
29 Jan
381.90
-0.92%
28 Jan
375.00
1.73%
27 Jan
385.50
-2.72%
23 Jan
387.00
-1.40%
22 Jan
385.00
0.48%
21 Jan
401.70
-4.54%
20 Jan
417.65
-4.32%
19 Jan
424.05
-1.51%
16 Jan
445.00
-4.28%
14 Jan
448.00
-1.35%
13 Jan
456.00
-1.77%
12 Jan
475.90
-3.89%
09 Jan
494.70
-3.80%
08 Jan
505.70
-2.54%
07 Jan
503.80
-0.11%
06 Jan
513.00
-2.09%
Cohance Lifesciences Limited Graph
Cohance Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Cohance Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 387.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 386.35 | 390.21 | 351.19 - 429.23 |
| 394.08 | 315.26 - 472.89 | ||
| 397.94 | 278.56 - 517.32 | ||
| Bearish Scenario | 386.35 | 382.49 | 344.24 - 420.74 |
| 378.62 | 302.90 - 454.35 | ||
| 374.76 | 262.33 - 487.19 |
Overview of Cohance Lifesciences Limited
ISIN
INE03QK01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
706,621
Market Cap
147,383,990,685
Last Dividend
0
Official Website
IPO Date
2020-03-09
DCF Diff
-199.76
DCF
570
Financial Ratios Every Investor Needs
Stock Dividend of COHANCE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 5 | 5 | 2022-09-12 | 2022-10-02 | |
| 2022-05-13 | May 13, 22 | 1 | 1 | 2022-05-17 | 2022-06-08 | |
| 2022-02-15 | February 15, 22 | 2 | 2 | 2022-02-16 | 2022-03-10 | |
| 2021-08-13 | August 13, 21 | 1 | 1 | 2021-08-17 | 2021-09-30 | |
| 2021-02-17 | February 17, 21 | 1 | 1 | 2021-02-18 | 2021-03-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,197.58 Cr | 375.72 Cr | 821.86 Cr | 0.6863 | 0.00 Cr | 250.50 Cr | 565.64 Cr | 267.87 Cr | 10.52 | 405.57 Cr | 0.2237 |
| 2024-03-31 | 1,051.35 Cr | 371.64 Cr | 679.71 Cr | 0.6465 | 0.00 Cr | 136.11 Cr | 540.12 Cr | 300.28 Cr | 11.80 | 408.99 Cr | 0.2856 |
| 2023-03-31 | 1,340.33 Cr | 588.22 Cr | 752.11 Cr | 0.5611 | 0.00 Cr | 118.27 Cr | 630.35 Cr | 411.29 Cr | 16.16 | 572.64 Cr | 0.3069 |
| 2022-03-31 | 1,320.22 Cr | 574.11 Cr | 746.11 Cr | 0.5651 | 10.35 Cr | 100.49 Cr | 633.39 Cr | 453.80 Cr | 17.83 | 579.49 Cr | 0.3437 |
| 2021-03-31 | 1,009.72 Cr | 437.18 Cr | 572.54 Cr | 0.5670 | 11.06 Cr | 76.58 Cr | 483.06 Cr | 362.34 Cr | 14.23 | 440.73 Cr | 0.3589 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 85.40 Cr | 3,031.75 Cr | 1,191.11 Cr | 1,696.5800 Cr | 279.07 Cr | 193.67 Cr | 166.57 Cr | 1,250.03 Cr | 0.00 Cr | 0.00 Cr | 144.95 Cr | 365.1900 Cr |
| 2024-03-31 | 47.23 Cr | 2,254.09 Cr | 203.42 Cr | 2,050.6635 Cr | 65.00 Cr | 17.77 Cr | 231.20 Cr | 786.78 Cr | 0.16 Cr | 0.00 Cr | 130.58 Cr | 106.8957 Cr |
| 2023-03-31 | 64.80 Cr | 1,965.74 Cr | 230.56 Cr | 1,735.1843 Cr | 70.34 Cr | 5.54 Cr | 333.29 Cr | 766.22 Cr | 25.57 Cr | 12.86 Cr | 117.10 Cr | 158.7658 Cr |
| 2022-03-31 | 44.56 Cr | 1,829.59 Cr | 302.41 Cr | 1,527.1803 Cr | 97.13 Cr | 52.56 Cr | 301.92 Cr | 561.95 Cr | 3.80 Cr | 37.33 Cr | 117.10 Cr | 210.2940 Cr |
| 2021-03-31 | 7.18 Cr | 1,474.47 Cr | 293.66 Cr | 1,180.8083 Cr | 143.04 Cr | 135.85 Cr | 212.72 Cr | 534.89 Cr | 27.85 Cr | 0.00 Cr | 361.19 Cr | 219.7480 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 288.1600 Cr | -255.3000 Cr | 3.3200 Cr | 132.4500 Cr | 38.3700 Cr | 85.6000 Cr | -155.7100 Cr | 343.9200 Cr | 22.7900 Cr | 0.0000 Cr | 74.1200 Cr |
| 2024-03-31 | 358.4831 Cr | -362.2532 Cr | -13.8023 Cr | 306.6962 Cr | -17.5716 Cr | 47.2312 Cr | -51.7869 Cr | 300.2805 Cr | -6.3512 Cr | 0.0000 Cr | 81.6149 Cr |
| 2023-03-31 | 450.9124 Cr | -194.8422 Cr | -235.8312 Cr | 165.1409 Cr | 20.2390 Cr | 64.8028 Cr | -285.7715 Cr | 559.7298 Cr | -26.3680 Cr | -203.6520 Cr | -29.3932 Cr |
| 2022-03-31 | 330.0002 Cr | -136.2069 Cr | -156.4121 Cr | 254.8135 Cr | 37.3816 Cr | 44.5638 Cr | -75.1867 Cr | 667.5898 Cr | -48.1944 Cr | -101.8260 Cr | -82.3369 Cr |
| 2021-03-31 | 383.4377 Cr | -311.3982 Cr | -76.5529 Cr | 272.5917 Cr | -4.5131 Cr | 7.1822 Cr | -110.8460 Cr | 467.6741 Cr | -41.5336 Cr | -25.4565 Cr | -26.2082 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 555.57 Cr | 141.13 Cr | 414.44 Cr | 0.7460 | 76.93 Cr | 74.08 Cr | 1.94 | 136.55 Cr | 0.1333 |
| 2025-06-30 | 549.31 Cr | 148.14 Cr | 401.17 Cr | 0.7303 | 267.85 Cr | 48.88 Cr | 1.91 | 86.24 Cr | 0.0890 |
| 2025-03-31 | 402.02 Cr | 204.43 Cr | 197.59 Cr | 0.4915 | 101.85 Cr | 42.01 Cr | 1.64 | 96.52 Cr | 0.1045 |
| 2024-12-31 | 307.15 Cr | 55.63 Cr | 251.52 Cr | 0.8189 | 188.23 Cr | 82.88 Cr | 3.26 | 110.30 Cr | 0.2698 |
| 2024-09-30 | 257.72 Cr | 52.06 Cr | 205.66 Cr | 0.7980 | 153.79 Cr | 82.21 Cr | 3.23 | 102.23 Cr | 0.3190 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 82.57 Cr | 320.28 Cr | 402.85 Cr | 603.48 Cr | 592.88 Cr | 1,845.24 Cr | 2,119.92 Cr | 5,568.49 Cr | 1,643.88 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 280.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,840.64 Cr |
| 2025-03-31 | 85.40 Cr | 205.01 Cr | 290.41 Cr | 284.83 Cr | 166.57 Cr | 888.59 Cr | 1,250.03 Cr | 3,031.75 Cr | 1,191.11 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 655.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,028.42 Cr |
| 2024-09-30 | 36.82 Cr | 619.06 Cr | 655.88 Cr | 185.65 Cr | 215.48 Cr | 1,167.65 Cr | 892.76 Cr | 2,505.56 Cr | 477.14 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 48.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 42.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 82.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 82.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 60.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-25 | September 25, 20 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,697.80 | ₹4,073,590,912,066.00 | ₹3,930,868.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,290.00 | ₹1,669,797,368,200.00 | ₹244,814.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,033.60 | ₹1,365,153,526,784.00 | ₹240,277.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,231.80 | ₹1,025,557,496,442.00 | ₹761,638.00 |
| Lupin Limited | LUPIN | ₹2,190.80 | ₹1,000,755,249,200.00 | ₹367,005.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹906.80 | ₹912,452,982,132.00 | ₹347,388.00 |
| Mankind Pharma Limited | MANKIND | ₹2,159.30 | ₹891,369,991,970.00 | ₹116,092.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,236.30 | ₹718,045,046,515.00 | ₹1,217,552.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,698.00 | ₹681,281,370,000.00 | ₹69,308.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,979.40 | ₹558,588,281,335.00 | ₹233,253.00 |
| Laurus Labs Limited | LAURUSLABS | ₹980.35 | ₹529,248,400,164.00 | ₹951,956.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,443.40 | ₹366,196,668,261.00 | ₹54,740.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,837.00 | ₹354,442,365,288.00 | ₹25,237.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,894.10 | ₹303,879,933,500.00 | ₹86,928.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,503.70 | ₹285,060,228,398.00 | ₹62,288.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,349.00 | ₹219,201,935,981.00 | ₹408,785.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,649.50 | ₹216,237,500,000.00 | ₹2,110.00 |
| Eris Lifesciences Limited | ERIS | ₹1,428.20 | ₹194,544,963,726.00 | ₹13,251.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,435.00 | ₹172,369,558,715.00 | ₹18,003.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹988.90 | ₹156,611,843,797.00 | ₹50,041.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹793.40 | ₹155,953,182,582.00 | ₹14,005.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹853.00 | ₹152,780,719,110.00 | ₹355,318.00 |
| Cohance Lifesciences Limited | COHANCE | ₹386.60 | ₹147,900,456,324.00 | ₹145,589.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,836.00 | ₹139,557,473,856.00 | ₹30,496.00 |
| Granules India Limited | GRANULES | ₹569.30 | ₹138,151,300,019.00 | ₹257,455.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹955.05 | ₹117,219,016,800.00 | ₹36,675.00 |
| Viyash Scientific Limited | VIYASH | ₹216.91 | ₹94,617,347,803.00 | ₹984,027.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,288.50 | ₹87,785,831,707.00 | ₹10,667.00 |
| Strides Pharma Science Limited | STAR | ₹863.10 | ₹79,554,269,453.00 | ₹148,496.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹789.55 | ₹71,570,570,978.00 | ₹68,670.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹452.50 | ₹69,278,681,245.00 | ₹71,811.00 |
| FDC Limited | FDC | ₹381.20 | ₹62,063,204,021.00 | ₹23,733.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹299.85 | ₹58,645,207,528.00 | ₹235,068.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹144.94 | ₹47,036,158,965.00 | ₹2,957,569.00 |
| Innova Captab Limited | INNOVACAP | ₹723.15 | ₹41,382,207,406.00 | ₹38,298.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹399.00 | ₹36,416,730,000.00 | ₹111,236.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.40 | ₹35,566,262,496.00 | ₹17,410.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹685.00 | ₹34,742,586,925.00 | ₹32,360.00 |
| Suven Life Sciences Limited | SUVEN | ₹146.50 | ₹33,324,941,000.00 | ₹213,933.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,995.00 | ₹32,995,334,925.00 | ₹5,638.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹306.35 | ₹30,721,545,713.00 | ₹21,387.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹397.75 | ₹28,003,887,063.00 | ₹27,679.00 |
Key Executives
Chief Commercial Officer
Declan Ryan
Gender: Not Specified
Year Born:
Chief Quality & Compliance Officer
K. Nagendra Babu
Gender: Not Specified
Year Born:
Chief Human Resources Officer
Gaurav Narain Bahadur
Gender: male
Year Born: 1970
Business Head of API
Gunjan Singh
Gender: male
Year Born:
Chief Financial Officer
Himanshu Agarwal
Gender: male
Year Born: 1970
Vice President of Corporate Affairs
Sunder Venkatraman
Gender: male
Year Born:
Executive Chairman
Vivek Sharma
Gender: male
Year Born:
Chief Executive Officer of CDMO Business
Yann D'Herve
Gender: male
Year Born:
Head of Investor Relations
Cyndrella Carvalho
Gender: female
Year Born:
FAQs about Cohance Lifesciences Limited
Who is the CEO of the company?
The CEO is Yann D'Herve.
What is the current market price of the stock?
The current price is ₹385.25.
What is the 52-week price range?
The range is ₹355.7-1123.4.
What is the market capitalization of the company?
The market capitalization is ₹14,738.40 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 39.86.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Cohance Lifesciences Limited (ISIN: INE03QK01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹14,738.40 crores and an average daily volume of 706,621 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.